Page 336 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

13. Mohs R, Doody R, Morris J, Ieni JR, Rogers SL, Perdomo CA, et al. Donepezil preserves functional
status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled attrition
study. Journal of the European College of Neuropsychopharmacology 1999;9(Supplement 5):S328.

14. Mohs R, Doody R, Morris J, Ieni J, Perdomo C, Pratt R, et al. Donepezil preserves activities of daily
living in alzheimer's disease patients: results from a one-year placebo-controlled functional survival
study. Neurology 2000;54(Suppl 3):A415.

15. Mohs R, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, et al. Donepezil preserves functional status
and improves cognition in alzheimer's disease patients: results from a 1-year prospective placebo-
controlled study. Journal of the American Geriatrics Society 2000;48(8):S46.

16. Petit H, Doody RS, Pratt RD. Donepezil improves cognition and global function in Alzheimer's
disease: Results from us and multinational phase III clinical trials CONFERENCE ABSTRACT.
11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October - 4th
November 1998. 1998:Abstract: P.4.008.

17. Pratt RD, Perdomo CA, Ieni JK. Long-term safety and tolerability of donepezil: results from a phase
iii extension trial of patients with mild to moderately severe alzheimer's disease. European Journal of
Neurology (Abstracts of the 4th Congress of the European Federation of Neurological Sciences,
September 7-11, Lisbon, Portugal 1999) 1999;6(Supplement 3):116.

18. Raskind M, Peskind E, Parys W, Wessel T. Galantamine produces long-term cognitive and functional
benefits in patients with Alzheimer's disease. Neurology 2000;54(Suppl 3):A468.

19. Reisberg B, Ferris S, Sahin K, Windscheif U, Möbius H. Results of a placebo-controlled 6-month
trial with memantine in moderate to severe alzheimer's disease (ad). Journal of the European College
of Neuropsychopharmacology (Abstracts of the 13th ECNP Congress, Munich, September 9-13,
2000) 2000;10(Supplement 3):S363.

20. Robert PH, Lebert F, Goni S, Touchon J. The impact of caregiver distress of donepezil treatment of
patients with mild alzheimer's disease. 152nd Annual Meeting of the American Psychiatric
Association. Washington DC, USA. 15-20th May, 1999. 1999.

21. Rockwood K, Kershaw P. Galantamine's clinical benefits are not offset by sleep disturbance: a 3-
month placebo-controlled study in patients with Alzheimer's disease. Neurobiology of Aging
2000;21:S239.

22. Rogers S, Perdomo C, Friedhoff L. Clinical Benefits are Maintained During Long-term Treatment of
Alzheimer's Disease with the Acetylcholinesterase Inhibitor, E2020 CONFERENCE ABSTRACT.
8th European College of Neuropsychopharmacology Congress. Venice, Italy. 30th September - 4th
October, 1995. 1995.

23. Rogers SL, Friedhoff LT. Donepezil improves cognition in patients with mild to moderate AD:
Results of ADAS-COG analysis in a 30-week phase III study. 10th European College of
Neuropsychopharmacology Congress. Vienna, Austria. 13th-17th September 1997. 1997.

24. Rogers SL, Friedhoff LT. Donepezil is well tolerated at clinically effective doses for the treatment of
Alzheimer's disease (AD). 10th European College of Neuropsychopharmacology Congress. Vienna,
Austria. 13th-17th September 1997. 1997.

Alzheimer's Drugs Page 203 of 205